XEGLYZE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XEGLYZE (XEGLYZE).
Glucagon-like peptide-1 (GLP-1) receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
| Metabolism | Primary proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP), followed by renal excretion of metabolites. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of elimination, with biliary/fecal elimination contributing about 30%. |
| Half-life | Terminal elimination half-life is 12 hours, supporting once-daily dosing in patients with normal renal function. |
| Protein binding | 95% bound to albumin. |
| Volume of Distribution | Vd is 0.8 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Oral bioavailability is 85%; not administered by other routes. |
| Onset of Action | Oral: 2 hours to detectable glucose lowering; maximal effect by 4–6 hours. |
| Duration of Action | Duration of action is 12–14 hours, allowing once-daily dosing; continued effect requires daily administration. |
100 mg orally once daily.
| Dosage form | LOTION |
| Renal impairment | eGFR ≥60 mL/min/1.73 m²: No adjustment. eGFR 45-59: 75 mg once daily. eGFR 30-44: 50 mg once daily. eGFR <30: Not recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: 50 mg once daily. Child-Pugh Class C: Not recommended. |
| Pediatric use | Not established; safety and efficacy in pediatric patients under 18 years have not been studied. |
| Geriatric use | No specific dose adjustment recommended based on age alone; monitor renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XEGLYZE (XEGLYZE).
| Breastfeeding | XEGLYZE is excreted into human breast milk; M/P ratio approximately 0.8. Limited data in breastfeeding women, but due to potential for infant hypoglycemia and long-term effects, a risk-benefit assessment is recommended; avoid use in nursing mothers unless clearly necessary. |
| Teratogenic Risk | First trimester: Animal studies show increased risk of malformations, including cardiac and neural tube defects; human data limited but suggest potential teratogenicity. Second and third trimesters: Risk of fetotoxicity (growth restriction) and neonatal hypoglycemia with exposure near term. |
■ FDA Black Box Warning
Risk of thyroid C-cell tumors, including medullary thyroid carcinoma; contraindicated in patients with personal or family history of MTC or MEN-2.
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma","Multiple endocrine neoplasia syndrome type 2","Hypersensitivity to active ingredient or excipients"]
| Precautions | ["Pancreatitis","Diabetic retinopathy complications","Hypoglycemia when used with insulin or sulfonylureas","Renal impairment","Acute kidney injury","Severe gastrointestinal disease"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, renal function, and liver enzymes; fetal surveillance includes growth ultrasound and nonstress test; neonatal monitoring for hypoglycemia and respiratory adaptation. |
| Fertility Effects | No known negative impact on male or female fertility in animal studies; human data limited. Use caution in women attempting conception due to potential early embryonic effects. |